UBS Investment Bank has announced coupon payments for its ETRACS Alerian MLP Index ETN Series B, which is traded on the NYSE Arca under the symbol "AMUB."
ETRACS Exchange Traded Notes (ETNs) are senior unsecured notes issued by UBS AG. These can be bought and sold through brokers or financial advisors. The investment in ETRACS ETNs carries risks, including potential loss of principal, and depends on the creditworthiness of UBS AG. Investors are not guaranteed any specific coupon or distribution amount. "We urge you to read the more detailed explanation of risks described under 'Risk Factors' in the applicable prospectus supplement for the ETRACS ETN," UBS advises.
UBS AG has registered a statement with the Securities and Exchange Commission (SEC) for these securities offerings. Potential investors are encouraged to read both the prospectus and applicable supplements before investing to understand fully all relevant terms and considerations. The offering documents for ETRACS ETN can be accessed via EDGAR on the SEC website at www.sec.gov.
UBS operates as a global wealth manager headquartered in Zurich, Switzerland, with operations across more than 50 markets worldwide. As of Q4 2024, UBS managed $6.1 trillion in invested assets. The company provides wealth management services alongside diversified asset management solutions and investment banking capabilities.
In the United States, activities such as securities underwriting, trading, brokerage services, and mergers & acquisitions advisory are conducted by UBS Securities LLC, a wholly owned subsidiary of UBS AG and a member of SIPC.
"This material is issued by UBS AG and/or any of its subsidiaries and/or any of its affiliates ('UBS')," states UBS regarding their information dissemination practices.
The trademarks Alerian MLP Index and AMZ belong to VettaFi under license agreements. Redistribution or reproduction of this communication without prior written permission from UBS is prohibited.
For media inquiries: Alison Keunen can be contacted at +1-212-713-2296 or alison.keunen@ubs.com. Institutional investors may call +1-877-387-2275 for further assistance.